Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 19/20 | 0.67 |
| ▸ | CDK12 | Q9NYV4 | 18/20 | 0.67 |
| ▸ | CDK7 | P50613 | 14/20 | 0.67 |
| ▸ | CCNH | P51946 | 14/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.67 |
| ▸ | CDK2 | P24941 | 11/20 | 0.67 |
| ▸ | CDK9 | P50750 | 9/20 | 0.67 |
| ▸ | CDK13 | Q14004 | 9/20 | 0.67 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.67 |
| ▸ | MNAT1 | P51948 | 9/20 | 0.63 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.63 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.60 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655034 | 1.00 | CCNK (0.67) | CCNKCDK12CDK7CCNHCCNA2 | |
| SCHEMBL16654911 | 0.88 | CCNK (0.68) | CCNKCDK12CDK7CCNHCCNA2 | |
| SCHEMBL16654909 | 0.88 | CCNK (0.68) | CCNKCDK12CDK7CCNHCCNA2 | |
| SCHEMBL18047399 | 0.85 | CCNK (0.65) | CCNKCDK12CDK7CCNHCCNA2 | |
| SCHEMBL16665736 | 0.85 | CCNK (0.65) | CCNKCDK12CDK7CCNHCCNA2 | |
| SCHEMBL16653960 | 0.84 | MAPK8 (0.66) | CCNKCDK12CDK7CCNHCCNA2 | |
| SCHEMBL18047408 | 0.84 | MAPK8 (0.66) | CCNKCDK12CDK7CCNHCCNA2 | |
| SCHEMBL16655001 | 0.84 | CDK7 (0.92) | CCNKCDK12CDK7CCNHCCNA2 | |
| SCHEMBL16654999 | 0.84 | CDK7 (0.92) | CCNKCDK12CDK7CCNHCCNA2 | |
| SCHEMBL16665770 | 0.83 | CCNK (0.65) | CCNKCDK12CDK7CCNHCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2019-09-26 | — | — | US | disclosed |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
| EP-3057954-A2 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Syros Pharmaceuticals, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015058163-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK7, CDK3, CDK17 | CCNK 10/4885CDK12 27/4885CDK7 1/4885 |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | CCNK 9/4885CDK12 27/4885CDK7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.